Pyxis Oncology Inc at Morgan Stanley Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Judah Frommer - Morgan Stanley - Analyst : <_ALACRA_META_ABSTRACT>So with that Laura. Maybe we can start with just a short overview of your programs for those less familiar with the Pyxis story.

Question: Judah Frommer - Morgan Stanley - Analyst : Okay, great. So with that in mind, can you talk a bit more about the differentiated approach in targeting the stroma with ADCs as opposed the other two are targeting cell surface receptors. Success has been limited clinically in stromal targeting. So maybe an ADC approach could have better prospects?

Question: Judah Frommer - Morgan Stanley - Analyst : Okay, great. And new in-licensing fact platform from Pfizer. Can you walk us through key differentiators with that platform? What makes it special in term and payload conjugation linker technology? And how can that impact the ultimate therapeutic window of your ADCs?

Question: Judah Frommer - Morgan Stanley - Analyst : Okay. That makes our assumption. And as you are moving to the Tier 1 program in your Phase 1 trial, what the level of enthusiasm looked like from investigators? What does that tell you about unmet need or willingness to trial such a new mechanism and maybe you could tie in recruitment and trial you and overall?

Question: Judah Frommer - Morgan Stanley - Analyst : Okay, got it. And you mentioned some of the doses. How can you put the doses reach in context of kind of narrowed or ADC landscape and what that could mean for the profile of the drug versus your expectations heading in and modeling material on trial.

Question: Judah Frommer - Morgan Stanley - Analyst : Got it. Okay. Maybe we could spend a minute on the safety profile generated thus far, what adverse events might you expect with the ETB mechanism and with the payload that we should be watching out for how would you characterize the qualitative safety update again on so far?

Question: Judah Frommer - Morgan Stanley - Analyst : Okay, perfect. And can you talk about evidence of activity you've seen so far? What gives you the confidence that there is anti-tumor activity with two oh one and the high doses aren't just reflective of a sink or potentially a less active.

Question: Judah Frommer - Morgan Stanley - Analyst : Okay. And you recently talked about narrowing down to four tumor types. Can you talk about how you chose to home in on those, how much of those of that decision was driven by clinical or versus preclinical data?

Question: Judah Frommer - Morgan Stanley - Analyst : Okay. And got it, how are you thinking about EDB expression as a marker for selecting patients? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 06, 2024 / 4:20PM, PYXS.OQ - Pyxis Oncology Inc at Morgan Stanley Global Healthcare Conference

Question: Judah Frommer - Morgan Stanley - Analyst : Okay, got it. And as we think about the data later this year, what measures should we think about beyond ORR and safety? Will we get a sense of potential durability based on duration of follow-up? And then can you tell us if it will be at a medical conference or whether you will do it at a company-sponsored?

Question: Judah Frommer - Morgan Stanley - Analyst : Okay. And a couple more boxes to check for us on the actual release. Can you help us with the number of patients, doses and scans? I'm going to be focusing on response rate, PFS, duration of response, right?

Question: Judah Frommer - Morgan Stanley - Analyst : So okay, that makes lot of sense. And how should we think about a win on the efficacy side? Are there bars you can help u?

Question: Judah Frommer - Morgan Stanley - Analyst : And if we look kind of next steps for two oh one, how do you think about positioning a stromal targeting ADC? And should we be thinking about

Question: Judah Frommer - Morgan Stanley - Analyst : Okay. That makes clear sense. And maybe just taking one step back. We talked about the four tumor types you've honed in on and adding a fifth and May, the fifth was soft tissue sarcoma again, just give us a little bit more detail on what led you to add that as a target yet.

Question: Judah Frommer - Morgan Stanley - Analyst : Okay. And then just following up on kind of the potential for combos here. You mentioned ADCs and checkpoint inhibitors and anything else we should we could we should consider from a modality perspective.

Question: Judah Frommer - Morgan Stanley - Analyst : Got it. Okay. I mean, I think this has been a great overview of the company. But maybe just to wrap up, we could focus on cash position and cash runway and then key events and investors should be focused on the next 6 to 12 months.

Question: Judah Frommer - Morgan Stanley - Analyst : Great. I think that's all we have. So thank you very much for the participation today.